BOC-GROUP
15.1.2020 15:29:10 CET | Business Wire | Press release
BOC Group , a global leader in enterprise business process analysis software (EBPA), and TIM Solutions , a leading provider of business process management (BPM) software for low-code human workflow automation, announced their strategic partnership today, focused on delivering accelerated digitalization of Business Process Automation at the enterprise level.
Both BOC Group and TIM have experienced that rapid automation of an existing manual process is the key first step in successful delivery of process automation. Once the automation is up-and-running, process analysis and design ensure that the process is quickly optimized further to reach cost reduction efficiencies of up-to 80%. What’s more, this approach delivers on all key targets of automation – reduction of redundant process activities, digitalization of manual tasks, and the overall improvement of customer experience. By combining TIM’s process automation with ADONIS’ process design and analysis capabilities, organizations can expect both a shorter time-to-value when automating processes, and a higher value-add delivered by the optimally designed automation.
The past months of collaboration between TIM and BOC Group have culminated today in a meeting of both management teams at BOC Group’s headquarters in Vienna, Austria, where the release of the ADONIS Process Automation module on the BOC Marketplace was announced. Customers of both partners can now benefit from this native integration that combines the intuitive process design, analysis and simulation of ADONIS with the seamless deployment, automation and monitoring of business processes in TIM’s process automation platform.
“Our customers seek to use low-code process automation as a key step in their digital journey. TIM is uniquely positioned as a simple, powerful and cost-effective automation platform that allows our customers to turn their process designs into automated workflows” mentioned Dr. Harald Kühn, BOC Group Board member. “We are excited about ADONIS Process Automation, powered by TIM, going live today on the BOC Marketplace” added Dr. Kühn.
“Having an optimal process design is a key success factor in rolling-out an automated human workflow. We are certain that the process analysis and design capabilities of ADONIS will be greatly beneficial when designing and optimizing automated workflows.” said TIM Solutions CEO, Mr. Hermann Filss “We are excited to be partnering with BOC Group as we look to directly profit from their global client footprint and rapidly spread the use of TIM around the world,” added Mr. Filss.
Both vendors have kicked-off campaigns to roll-out the integration as they look to capture a very active process automation market with their unique combined offering. Interested parties are welcome to schedule a Proof of Concept through the BOC Marketplace .
About BOC Group
BOC is a global leader in Enterprise Modelling Software across the Enterprise Business Process Analysis (EBPA), Governance Risk and Compliance (GRC) and Enterprise Architecture (EA) domains. Enabling customers to successfully and continuously re-design their digital enterprise to ensure business success at every level of the organization.
ADONIS customers include:
- Allianz
- Comcast
- Emerson
- Hilti
- Telefonica
BOC delivers products and services globally to over 1,000 companies supported by over 90 partners around the globe.
About TIM Solutions
TIM Solutions is focused on developing a simple method for automating and managing human workflows. They provide comprehensive solutions and consulting to their customers in the field Business Process Automation and Business Process Management.
TIM customers include:
- BMW AG
- Deutsche Bahn AG
- ManpowerGroup
- E.ON SE
- Tata Consultancy Services
TIM BPM Suite is used by more than 310 companies in 56 countries around the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005507/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom